Liver disease kills approximately two million people per annum. Although organ transplant is a viable option to treat disease, many patients are not candidates for this type of treatment or die on the transplant waiting list.

Stimuliver is developing a disruptive liver implant to treat critically failing liver function in humans. 
The implant will be placed underneath the skin to ‘top up’ the patient’s reduced liver function. Lab engineered liver tissue will be produced from human stem cells, providing a scalable and renewable source of human liver tissue. The development of the liver implant to clinical grade will provide patients with a renewable treatment option for their disease.



Biotechnology

Health Care

Life Sciences

Medical Devices

Stimuliver

David Hay

Reinout Hesselink

Joakim Nguyen Sørensen

Giles Dudley

Dagmara Szkolnicka

Stimuliver

Org chart

Similar companies